<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01890148</url>
  </required_header>
  <id_info>
    <org_study_id>D3551C00003</org_study_id>
    <nct_id>NCT01890148</nct_id>
  </id_info>
  <brief_title>Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069</brief_title>
  <official_title>An Explorative Investigation to Study the Relationship and Distribution of Neutrophils in Bronchial Mucosal Tissue, Induced Sputum and Blood After Administration of 45 mg BD AZD 5069 for 4 Weeks to Patients With Moderate Persistent Neutrophilic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Distribution of neutrophils in bronchial mucosal tissue in asthma patients before and after 4
      wk treatment with AZD 5069
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose is to investigate the bronchial tissue neutrophil counts and distribution in
      asthma patients after 4 week oral treatment with AZD 5069
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summary for Change From Baseline of Mean Global Semi-quantitative Score Values for Neutrophils in Bronchial Biopsies</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Change from baseline reflects the Week 4 value minus the baseline value. Baseline value is Day-14 measurement.
For semi-quantitative scores, 1= few number of Neutrophils, 2= moderate number of Neutrophils, 3= abundant of Neutrophils. For this end point the reduction in mean of semi-quantitative (arbitrary) scores indicates better result, i.e. lower numbers of Neutrophils.
The scores given for the biopsies taken at screening and end of treatment is the mean global semi-quantitative scores for the three compartments intraepithelial, subepithelial and submucosal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary for Change From Baseline Neutrophils in Sputum</measure>
    <time_frame>Baseline, Day 8, Day 22 and Day29</time_frame>
    <description>Change from Baseline reflects the Day 8, Day22 and Day29 minus the baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary for Change From Baseline Neutrophil Cell Counts in Blood</measure>
    <time_frame>Baseline, Day 2, Day 8, Day 15, Day 22, Day29 and Day 34</time_frame>
    <description>Change from Baseline reflects the Day 2, Day 8, Day 15, Day 22, Day29 and Day 34 minus the baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Summary for Change From Baseline for IL-8 by Type of Sample</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Change from baseline reflects the Day 29 value minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary for Change From Baseline for GRO-alpha by Type of Sample</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Change from baseline reflects the Day 29 value minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary for Change From Baseline for MMP-9 by Type of Sample</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Change from baseline reflects the Day 29 value minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary Statistics for AUC0-4hrs on Day 29/ Visit T7 (PK Analysis Set)</measure>
    <time_frame>At 0, 0.5, 1, 1.5, 2, 2.5, 3, 4 hours post dose on Day 29 (Visit T7)</time_frame>
    <description>Summary statistics including geometric mean and standard error for AUC0-4hrs on Day 29/ Visit T7 (PK analysis set).
Plasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary Statistics for Cmin on Day 29/ Visit T7 (PK Analysis Set)</measure>
    <time_frame>At 0, 0.5, 1, 1.5, 2, 2.5, 3, 4 hours post dose on Day 29 (Visit T7)</time_frame>
    <description>Summary statistics including geometric mean and standard error for Cmin on Day 29/ Visit T7 (PK analysis set).
Plasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary Statistics for Cmax on Day 29/ Visit T7 (PK Analysis Set)</measure>
    <time_frame>At 0, 0.5, 1, 1.5, 2, 2.5, 3, 4 hours post dose on Day 29 (Visit T7)</time_frame>
    <description>Summary statistics including geometric mean and standard error for Cmax on Day 29/ Visit T7 (PK analysis set).
Plasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Summary of number of adverse events (safety set)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Summary of number of participants with adverse events (safety set)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary Statistics for Patient Diary Variables (Day Time)</measure>
    <time_frame>Up to 44 days</time_frame>
    <description>Summary statistics for patient diary variable, observations with no asthma symptoms (day time), by period (safety set).
The screening period was Day -14 to -1. Period 1 was the first half of treatment period, Day 1 to daytime record Day 15. Period 2 was the second half of treatment period, night-time record Day 15 to night-time record Day 29+1.
One participant left the study on day 2, due to adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary Statistics for Patient Diary Variables (Night Time)</measure>
    <time_frame>Up to 44 days</time_frame>
    <description>Summary statistics for patient diary variable, observations with no asthma symptoms (night time), by period (safety set).
The screening period was Day -14 to -1. Period 1 was the first half of treatment period, Day 1 to daytime record Day 15. Period 2 was the second half of treatment period, night-time record Day 15 to night-time record Day 29+1.
One participant left the study on day 2, due to adverse event.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral BD administration of 45 mg AZD5069</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5069</intervention_name>
    <description>oral BD administration of 45 mg AZD5069</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients of Caucasian origin, aged between 18 to 65 years, inclusive,
             at the time informed consent is obtained.

          2. Physician based (according to GINA 2011) diagnosis of asthma for at least 6 months
             prior to the date informed consent is obtained and confirmed by 1 of the detailed
             respiratory criteria stated in the CSP

          3. Morning prebronchodilator (ie, after abstinence from short-acting and long-acting
             ß-agonist treatment for ≥ 6 and ≥ 12 hours, respectively) FEV1 of ≥70% of predicted
             normal (PN) for age, sex and height at enrolment

          4. Increased number of neutrophils in induced sputum samples at baseline, with a relative
             neutrophil count of ≥ 50% of total sputum cell count

          5. Physician prescribed daily use of medium or high dose ICS (≥ fluticasone 250 μg to ≤
             1.000 µg or the equivalent daily, as defined in GINA 2011; see CSP Appendix E) plus
             LABA.

        Exclusion Criteria:

          1. History of clinically relevant allergies or idiosyncrasies to AZD5069 or other
             investigational CXCR2 antagonists, or any inactive ingredient(s) of the IMP, or
             tool-substances (eg, salbutamol, local anaesthetics) used for the purpose of this
             study

          2. History of severe asthma exacerbation requiring hospitalization within the last 12
             months before screening.

          3. Asthma exacerbation requiring a treatment course of systemic (ie, oral or parenteral)
             corticosteroids within the 3 months before screening or ≥ 3 courses within the last 12
             months before screening.

          4. Moderate to severe airflow limitation (FEV1 &lt;70% PN)

          5. Any chronic lower respiratory disease other than asthma (see CSP for details) that, as
             judged by the Investigator or Medical Monitor, would interfere with the evaluation of
             the IMP or interpretation of patient safety or study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Richter, MSD</last_name>
    <role>Study Director</role>
    <affiliation>Astrazeneca Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klaus F Rabe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lung Clinic Grosshansdorf Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grosshansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2013</study_first_submitted>
  <study_first_submitted_qc>June 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2013</study_first_posted>
  <results_first_submitted>June 29, 2015</results_first_submitted>
  <results_first_submitted_qc>January 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2016</results_first_posted>
  <last_update_submitted>January 28, 2016</last_update_submitted>
  <last_update_submitted_qc>January 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Thirteen patients were screened; 8 patients were screening failures, 5 patients were enrolled in the study and received treatment with AZD5069.
First patient enrolled: 11 March 2014. Last patient completed: 18 August 2014.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD5069</title>
          <description>AZD5069 45mg oral twice daily (BID)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD5069</title>
          <description>AZD5069 45mg oral twice daily (BID)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.8" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summary for Change From Baseline of Mean Global Semi-quantitative Score Values for Neutrophils in Bronchial Biopsies</title>
        <description>Change from baseline reflects the Week 4 value minus the baseline value. Baseline value is Day-14 measurement.
For semi-quantitative scores, 1= few number of Neutrophils, 2= moderate number of Neutrophils, 3= abundant of Neutrophils. For this end point the reduction in mean of semi-quantitative (arbitrary) scores indicates better result, i.e. lower numbers of Neutrophils.
The scores given for the biopsies taken at screening and end of treatment is the mean global semi-quantitative scores for the three compartments intraepithelial, subepithelial and submucosal.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AZD5069</title>
            <description>AZD5069 45mg oral twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary for Change From Baseline of Mean Global Semi-quantitative Score Values for Neutrophils in Bronchial Biopsies</title>
          <description>Change from baseline reflects the Week 4 value minus the baseline value. Baseline value is Day-14 measurement.
For semi-quantitative scores, 1= few number of Neutrophils, 2= moderate number of Neutrophils, 3= abundant of Neutrophils. For this end point the reduction in mean of semi-quantitative (arbitrary) scores indicates better result, i.e. lower numbers of Neutrophils.
The scores given for the biopsies taken at screening and end of treatment is the mean global semi-quantitative scores for the three compartments intraepithelial, subepithelial and submucosal.</description>
          <population>PD analysis set</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary for Change From Baseline Neutrophils in Sputum</title>
        <description>Change from Baseline reflects the Day 8, Day22 and Day29 minus the baseline value.</description>
        <time_frame>Baseline, Day 8, Day 22 and Day29</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AZD5069</title>
            <description>AZD5069 45mg oral twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary for Change From Baseline Neutrophils in Sputum</title>
          <description>Change from Baseline reflects the Day 8, Day22 and Day29 minus the baseline value.</description>
          <population>PD analysis set</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.294" spread="3.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.670" spread="3.751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.849" spread="1.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary for Change From Baseline Neutrophil Cell Counts in Blood</title>
        <description>Change from Baseline reflects the Day 2, Day 8, Day 15, Day 22, Day29 and Day 34 minus the baseline value</description>
        <time_frame>Baseline, Day 2, Day 8, Day 15, Day 22, Day29 and Day 34</time_frame>
        <population>PD Analysis</population>
        <group_list>
          <group group_id="O1">
            <title>AZD5069</title>
            <description>AZD5069 45mg oral twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary for Change From Baseline Neutrophil Cell Counts in Blood</title>
          <description>Change from Baseline reflects the Day 2, Day 8, Day 15, Day 22, Day29 and Day 34 minus the baseline value</description>
          <population>PD Analysis</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.517" spread="0.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.494" spread="0.559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.985" spread="0.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.658" spread="0.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.178" spread="1.375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.306" spread="0.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary for Change From Baseline for IL-8 by Type of Sample</title>
        <description>Change from baseline reflects the Day 29 value minus the baseline value.</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AZD5069</title>
            <description>AZD5069 45mg oral twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary for Change From Baseline for IL-8 by Type of Sample</title>
          <description>Change from baseline reflects the Day 29 value minus the baseline value.</description>
          <population>PD analysis set</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-8 in Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.88" spread="34.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8 in Sputum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5780.75" spread="3763.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary for Change From Baseline for GRO-alpha by Type of Sample</title>
        <description>Change from baseline reflects the Day 29 value minus the baseline value.</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AZD5069</title>
            <description>AZD5069 45mg oral twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary for Change From Baseline for GRO-alpha by Type of Sample</title>
          <description>Change from baseline reflects the Day 29 value minus the baseline value.</description>
          <population>PD analysis set</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GRO-alpha in Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.75" spread="98.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GRO-alpha in Sputum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7352.50" spread="22373.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary for Change From Baseline for MMP-9 by Type of Sample</title>
        <description>Change from baseline reflects the Day 29 value minus the baseline value.</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>PD analysis</population>
        <group_list>
          <group group_id="O1">
            <title>AZD5069</title>
            <description>AZD5069 45mg oral twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary for Change From Baseline for MMP-9 by Type of Sample</title>
          <description>Change from baseline reflects the Day 29 value minus the baseline value.</description>
          <population>PD analysis</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMP-9 in Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-157.75" spread="289.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP-9 in Sputum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-80.75" spread="178.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary Statistics for AUC0-4hrs on Day 29/ Visit T7 (PK Analysis Set)</title>
        <description>Summary statistics including geometric mean and standard error for AUC0-4hrs on Day 29/ Visit T7 (PK analysis set).
Plasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.</description>
        <time_frame>At 0, 0.5, 1, 1.5, 2, 2.5, 3, 4 hours post dose on Day 29 (Visit T7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD5069</title>
            <description>AZD5069 45mg oral twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary Statistics for AUC0-4hrs on Day 29/ Visit T7 (PK Analysis Set)</title>
          <description>Summary statistics including geometric mean and standard error for AUC0-4hrs on Day 29/ Visit T7 (PK analysis set).
Plasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.</description>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8571.72" spread="2421.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary Statistics for Cmin on Day 29/ Visit T7 (PK Analysis Set)</title>
        <description>Summary statistics including geometric mean and standard error for Cmin on Day 29/ Visit T7 (PK analysis set).
Plasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.</description>
        <time_frame>At 0, 0.5, 1, 1.5, 2, 2.5, 3, 4 hours post dose on Day 29 (Visit T7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD5069</title>
            <description>AZD5069 45mg oral twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary Statistics for Cmin on Day 29/ Visit T7 (PK Analysis Set)</title>
          <description>Summary statistics including geometric mean and standard error for Cmin on Day 29/ Visit T7 (PK analysis set).
Plasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.</description>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="466.92" spread="272.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary Statistics for Cmax on Day 29/ Visit T7 (PK Analysis Set)</title>
        <description>Summary statistics including geometric mean and standard error for Cmax on Day 29/ Visit T7 (PK analysis set).
Plasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.</description>
        <time_frame>At 0, 0.5, 1, 1.5, 2, 2.5, 3, 4 hours post dose on Day 29 (Visit T7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD5069</title>
            <description>AZD5069 45mg oral twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary Statistics for Cmax on Day 29/ Visit T7 (PK Analysis Set)</title>
          <description>Summary statistics including geometric mean and standard error for Cmax on Day 29/ Visit T7 (PK analysis set).
Plasma concentration data beyond 0.5 hrs post dose at Day 29 were missing for one patient. For this patient only Cmin value was reported and the AUC0-4hrs and Cmax values were not reported.</description>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3565.76" spread="762.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events</title>
        <description>Summary of number of adverse events (safety set)</description>
        <time_frame>Up to 40 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD5069</title>
            <description>AZD5069 45mg oral twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events</title>
          <description>Summary of number of adverse events (safety set)</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total number of unique AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total number of AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total number of SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Summary of number of participants with adverse events (safety set)</description>
        <time_frame>Up to 40 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD5069</title>
            <description>AZD5069 45mg oral twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Summary of number of participants with adverse events (safety set)</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total number of subjects with at least one AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects withdrawn from study due to AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary Statistics for Patient Diary Variables (Day Time)</title>
        <description>Summary statistics for patient diary variable, observations with no asthma symptoms (day time), by period (safety set).
The screening period was Day -14 to -1. Period 1 was the first half of treatment period, Day 1 to daytime record Day 15. Period 2 was the second half of treatment period, night-time record Day 15 to night-time record Day 29+1.
One participant left the study on day 2, due to adverse event.</description>
        <time_frame>Up to 44 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD5069</title>
            <description>AZD5069 45mg oral twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary Statistics for Patient Diary Variables (Day Time)</title>
          <description>Summary statistics for patient diary variable, observations with no asthma symptoms (day time), by period (safety set).
The screening period was Day -14 to -1. Period 1 was the first half of treatment period, Day 1 to daytime record Day 15. Period 2 was the second half of treatment period, night-time record Day 15 to night-time record Day 29+1.
One participant left the study on day 2, due to adverse event.</description>
          <units>Observations</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Observation</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Obs. with No asthma symptoms (Screening; n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obs. with No asthma symptoms (Period1; n=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obs. with No asthma symptoms (Period2; n=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary Statistics for Patient Diary Variables (Night Time)</title>
        <description>Summary statistics for patient diary variable, observations with no asthma symptoms (night time), by period (safety set).
The screening period was Day -14 to -1. Period 1 was the first half of treatment period, Day 1 to daytime record Day 15. Period 2 was the second half of treatment period, night-time record Day 15 to night-time record Day 29+1.
One participant left the study on day 2, due to adverse event.</description>
        <time_frame>Up to 44 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD5069</title>
            <description>AZD5069 45mg oral twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary Statistics for Patient Diary Variables (Night Time)</title>
          <description>Summary statistics for patient diary variable, observations with no asthma symptoms (night time), by period (safety set).
The screening period was Day -14 to -1. Period 1 was the first half of treatment period, Day 1 to daytime record Day 15. Period 2 was the second half of treatment period, night-time record Day 15 to night-time record Day 29+1.
One participant left the study on day 2, due to adverse event.</description>
          <units>Observations</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>observations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Obs. with No asthma symptoms (Screening; n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obs. with No asthma symptoms (Period1; n=69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obs. with No asthma symptoms (Period2; n=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD5069</title>
          <description>AZD5069 45mg oral twice daily (BID)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutropil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Obstructive airways</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Larsson, Bengt</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+46 (0) 317064277</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

